WO2003053451A1 - Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract - Google Patents
Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract Download PDFInfo
- Publication number
- WO2003053451A1 WO2003053451A1 PCT/EP2002/013032 EP0213032W WO03053451A1 WO 2003053451 A1 WO2003053451 A1 WO 2003053451A1 EP 0213032 W EP0213032 W EP 0213032W WO 03053451 A1 WO03053451 A1 WO 03053451A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ionic
- fats
- agent
- gel
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
Definitions
- the invention relates to an agent which, after oral ingestion in humans or in animals in the gastrointestinal tract, reduces the extent of the absorption of dietary fats. Due to the reduced absorption of dietary fats, the agent according to the invention is intended for use in reduction diets to reduce the amount of calories consumed and to lower the cholesterol level.
- Obesity in humans or animals is caused by the excessive intake of high-calorie food.
- Herbal slimming agents contain swelling agents such as alginic acid or karaya gum, which are supposed to have a satiating effect due to their volume stimulus.
- Sypathomimetics are also used as appetite suppressants to support weight loss. Sympathomimetics are said to have a stimulating effect and counteract the tiredness that occurs with reduction diets. Sympathomimetics are absorbed into the bloodstream. They can trigger significant side effects like high blood pressure. In the case of reduction diets, attempts can be made to absorb food fats by means of lipase inhibitors such as. B. Orlistat (U.S. Patent 4,598,089). Orlistat is filled into capsules and used for weight loss in the context of reduction diets. Orlistat is said to be used in the gastrointestinal tract for the absorption of certain dietary fats
- Orlistat intervenes in metabolic processes in the body. Numerous side effects are described that suggest further pharmacological activities of the substance in the body.
- ionic or nonionic cellulose ethers are given as solutions, suspensions, powders and granules or in the form of tablets and capsules.
- Hydroxyethyl cellulose with a high viscosity is preferably given as the cellulose ether. Hydroxyethyl cellulose is used as a solution or aqueous suspension before, with or after meals ingested. A preferred form of preparation is an aqueous suspension which only develops a gel-like consistency in the stomach after ingestion.
- the cellulose derivatives used for the agent according to the invention are practically not absorbed. They have no side effects.
- ionic or nonionic gelling agents for the preparation of the agent according to the invention are carmellose, hypromellose, hydroxyethyl cellulose, hydroxypropyl cellulose, ethyl methyl cellulose and
- Methylcellulose Other gelling agents of other substance classes such as B. Starch derivatives can be used to support gel formation.
- the ingredients are mixed and processed into granules.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002352075A AU2002352075A1 (en) | 2001-12-10 | 2002-11-21 | Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10160409.2 | 2001-12-10 | ||
DE10160409A DE10160409A1 (en) | 2001-12-10 | 2001-12-10 | Fat resorption composition, useful for treating obesity in humans and animals, comprises ionic and/or nonionic cellulose ether that forms a gel in the gastro-intestinal tract |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003053451A1 true WO2003053451A1 (en) | 2003-07-03 |
Family
ID=7708551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/013032 WO2003053451A1 (en) | 2001-12-10 | 2002-11-21 | Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002352075A1 (en) |
DE (1) | DE10160409A1 (en) |
WO (1) | WO2003053451A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
JP2010506957A (en) * | 2006-10-20 | 2010-03-04 | ダウ グローバル テクノロジーズ インコーポレイティド | Use of water-soluble cellulose derivatives to prevent or treat metabolic syndrome |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2011139763A1 (en) * | 2010-04-29 | 2011-11-10 | Dow Global Technologies Llc | Methods and compositions for inducing satiety |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010506956A (en) * | 2006-10-20 | 2010-03-04 | ダウ グローバル テクノロジーズ インコーポレイティド | Methods for preventing or treating metabolic syndrome |
MX2011004087A (en) * | 2008-10-17 | 2012-07-04 | Us Of America Representados Por The Secretary Of Agriculture | Methods of reducing absorption of trans fatty acids using water-insoluble cellulose derivatives. |
US20110230439A1 (en) * | 2008-10-17 | 2011-09-22 | Kerr Anderson | Methods of reducing absorption of trans fatty acids using water-soluble cellulose derivatives |
IN2014CN02795A (en) * | 2011-10-19 | 2015-07-03 | Dow Global Technologies Llc | |
WO2013059065A1 (en) * | 2011-10-19 | 2013-04-25 | Dow Global Technologies Llc | Methods and compositions for inducing satiety |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5462742A (en) * | 1990-11-22 | 1995-10-31 | Pharmacia Ab | Gel-forming liquid dietary fibre composition |
WO2000013667A1 (en) * | 1998-09-08 | 2000-03-16 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
-
2001
- 2001-12-10 DE DE10160409A patent/DE10160409A1/en not_active Withdrawn
-
2002
- 2002-11-21 AU AU2002352075A patent/AU2002352075A1/en not_active Abandoned
- 2002-11-21 WO PCT/EP2002/013032 patent/WO2003053451A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5462742A (en) * | 1990-11-22 | 1995-10-31 | Pharmacia Ab | Gel-forming liquid dietary fibre composition |
WO2000013667A1 (en) * | 1998-09-08 | 2000-03-16 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
Non-Patent Citations (4)
Title |
---|
CARR T P ET AL: "INCREASED INTESTINAL CONTENTS VISCOSITY REDUCES CHOLESTEROL ABSORPTION EFFICIENCY IN HAMSTERS FED HYDROXYPROPYL METHYLCELLULOSE", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 126, no. 5, May 1996 (1996-05-01), pages 1463 - 1469, XP009006968, ISSN: 0022-3166 * |
MAKI K C ET AL: "HIGH-MOLECULAR-WEIGHT HYDROXYPROPYLMETHYLCELLULOSE TAKEN WITH OR BETWEEN MEALS IS HYPOCHOLESTEROLEMIC IN ADULT MEN", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 130, no. 7, July 2000 (2000-07-01), pages 1705 - 1710, XP001083790, ISSN: 0022-3166 * |
SMITS C H M ET AL: "THE INHIBITORY EFFECT OF CARBOXYMETHYLCELLULOSE WITH HIGH VISCOSITY ON LIPID ABSORPTION IN BROILER CHICKENS COINCIDES WITH REDUCED BILE SALT CONCENTRATION AND RAISED MICROBIAL NUMBERS IN THE SMALL INTESTINE", POULTRY SCIENCE, CHAMPAIGN, IL, US, vol. 77, no. 10, October 1998 (1998-10-01), pages 1534 - 1539, XP009006963, ISSN: 0032-5791 * |
TOPPING D: "HYDROXYPROPYLMETHYLCELLULOSE, VISCOSITY, AND PLASMA CHOLESTEROL CONTROL", NUTRITION REVIEWS, ALLEN PRESS, LAWRENCE, KS, US, vol. 52, no. 5, May 1994 (1994-05-01), pages 176 - 178, XP009006971, ISSN: 0029-6643 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
JP2010506957A (en) * | 2006-10-20 | 2010-03-04 | ダウ グローバル テクノロジーズ インコーポレイティド | Use of water-soluble cellulose derivatives to prevent or treat metabolic syndrome |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
WO2011139763A1 (en) * | 2010-04-29 | 2011-11-10 | Dow Global Technologies Llc | Methods and compositions for inducing satiety |
JP2013525447A (en) * | 2010-04-29 | 2013-06-20 | ダウ グローバル テクノロジーズ エルエルシー | Methods and compositions for inducing satiety |
CN102905762A (en) * | 2010-04-29 | 2013-01-30 | 陶氏环球技术有限责任公司 | Methods and compositions for inducing satiety |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
Also Published As
Publication number | Publication date |
---|---|
AU2002352075A1 (en) | 2003-07-09 |
DE10160409A1 (en) | 2003-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003053451A1 (en) | Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract | |
EP0575846B1 (en) | Food and feedstuff containing lipase inhibitors | |
DE69531900T2 (en) | FOOD CONTAINING CEREALS WITH A HIGH SOLUBLE SOLVENT | |
DE60207877T2 (en) | Composition containing procyanidins for reducing appetite in mammals | |
US5932561A (en) | Dietary composition with lipid binding properties for weight management and serum lipid reduction | |
EP1494655A1 (en) | Agent for producing a sensation of satiety and for weight loss | |
DE602004006860T2 (en) | CAPSAICINOID-CONTAINING PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
CN104814901B (en) | One kind prevention striae of pregnancy gel and preparation method thereof | |
DE602004003577T2 (en) | Floating oral formulations with controlled release of betaine | |
JP2664753B2 (en) | Mixed composition for the treatment of hypercholesterolemia | |
DE60002484T2 (en) | COMPOSITION THAT CONTAINS AN ALPHA AMYLASE INHIBITOR AND AT LEAST ONE PHYSIOLOGICALLY ACCEPTABLE COMPONENT THAT CAN REDUCE THE INTESTINAL ABSORPTION OF "FAST SUGARS" | |
WO2009036906A1 (en) | Composition with laxative/antifoam active ingredient combination for the treatment of constipation | |
WO1998018346A2 (en) | Neutral-tasting microcapsules, method for their manufacturing and their use | |
DE10060750A1 (en) | Food supplement product for intestinal activation | |
DE69919963T2 (en) | Magnesium oxide-containing laxative | |
DE69232126T3 (en) | Ingestible preparations containing water-soluble, highly viscous cellulose ethers | |
EP2688577B1 (en) | Digestive symptom ameliorating composition | |
DE10044846A1 (en) | Agent with prolonged gastric residence time to produce a long-lasting satiety effect and its use | |
DE19528524A1 (en) | Calcium-containing agent for intestinal phosphate binding and process for its preparation | |
CN1138296A (en) | Use of dimeticone for treating constipation | |
DE2850791A1 (en) | PHARMACEUTICAL AGENT FOR SUPPRESSING THE STOMACH RETURN | |
EP0256353A2 (en) | Pharmaceutical therapy against the bad absorption of food or oral drugs | |
US20100166888A1 (en) | Composition and method for the control of organoleptic properties of bodily fluids and secretions | |
WO2002069987A2 (en) | Agent for treating diabetes mellitus | |
JP2959996B2 (en) | Diet composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |